Principal Financial Group
ADMA icon

Principal Financial Group’s ADMA Biologics ADMA Stock Holding History

Principal Financial Group’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.5M Sell
1,379,703
-10,610
-0.8% -$96.7K 0.01% 1326
2026
Q1 		$12.5M Sell
1,390,313
-12,987
-0.9% -$205K 0.01% 1207
2025
Q4 		$25.6M Buy
1,403,300
+80,259
+6% +$1.35M 0.01% 748
2025
Q3 		$19.4M Sell
1,323,041
-223,394
-14% -$3.83M 0.01% 887
2025
Q2 		$28.2M Buy
1,546,435
+258,314
+20% +$5.27M 0.01% 666
2025
Q1 		$25.6M Buy
1,288,121
+29,107
+2% +$503K 0.01% 690
2024
Q4 		$21.6M Buy
1,259,014
+64,793
+5% +$1.22M 0.01% 814
2024
Q3 		$23.9M Buy
1,194,221
+1,059,394
+786% +$16.5M 0.01% 749
2024
Q2 		$1.51M Sell
134,827
-1,433
-1% -$12K ﹤0.01% 1807
2024
Q1 		$899K Sell
136,260
-22,374
-14% -$122K ﹤0.01% 1880
2023
Q4 		$717K Buy
158,634
+23,844
+18% +$88.2K ﹤0.01% 1884
2023
Q3 		$483K Buy
134,790
+30,088
+29% +$116K ﹤0.01% 1961
2023
Q2 		$386K Buy
104,702
+2,225
+2% +$8.25K ﹤0.01% 2008
2023
Q1 		$339K Sell
102,477
-6,673
-6% -$23.1K ﹤0.01% 2059
2022
Q4 		$424K Buy
109,150
+29,362
+37% +$90.6K ﹤0.01% 2015
2022
Q3 		$194K Sell
79,788
-54,586
-41% -$131K ﹤0.01% 2212
2022
Q2 		$266K Buy
134,374
+119,333
+793% +$235K ﹤0.01% 2218
2022
Q1 		$28K Sell
15,041
-847
-5% -$1.32K ﹤0.01% 2512
2021
Q4 		$22K Sell
15,888
-2,896
-15% -$3.81K ﹤0.01% 2509
2021
Q3 		$21K Sell
18,784
-3,043
-14% -$4.26K ﹤0.01% 2569
2021
Q2 		$35K Sell
21,827
-338,684
-94% -$596K ﹤0.01% 2591
2021
Q1 		$634K Buy
360,511
+24,953
+7% +$57.1K ﹤0.01% 2088
2020
Q4 		$655K Buy
335,558
+193,338
+136% +$406K ﹤0.01% 2039
2020
Q3 		$340K Buy
142,220
+58,428
+70% +$160K ﹤0.01% 2104
2020
Q2 		$246K Buy
+83,792
New +$241K ﹤0.01% 2135

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Principal Financial Group's ADMA Position: Q2 2026 in Review

Principal Financial Group reduced its ADMA Biologics (ADMA) stake by 0.76% in Q2 2026, selling an estimated $96.7K and leaving 1,379,703 shares worth $11.5M. The position accounts for 0.01% of the portfolio, ranked #1326.

Principal Financial Group first reported a position in ADMA in Q2 2020 and has held it in 25 quarters since. The position peaked at $28.2M in Q2 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Principal Financial Group held 1,379,703 shares of ADMA Biologics worth $11.5M as of Q2 2026.
  • Principal Financial Group sold 10,610 ADMA Biologics shares in Q2 2026, an estimated $96.7K.
  • ADMA Biologics made up 0.01% of Principal Financial Group's portfolio in Q2 2026, its #1326 holding.
  • Principal Financial Group first reported a position in ADMA Biologics in Q2 2020 and has held it in 25 quarters since.
  • Principal Financial Group's ADMA Biologics position peaked at $28.2M in Q2 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.